Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
February 9th, 2016
This protocol describes the use of excised intestinal tissue preparations or "intestinal sacs" as an ex vivo model of intestinal barrier function. This model may be used to assess integrity of both the epithelial barrier and the mucous gel layer at specific intestinal sites in animal models of digestive disease.
The overall goal of this procedure is to assess the localized intestinal integrity in animal models of gastrointestinal disease.This method can help answer key quesitons about gastrointestinal disease, such as whether musosal integrity is lost or if there is an increase in uptake of a specific molecule or bacteria during disease.The main advantage of this technique is that it can be used to assess specific areas within the gastrointestinal tract.To prepare the gastrointestinal tract, begin by spraying the abdomen and thorax of the mouse with 70 percent ethanol and use scissors to make a horizontal incision in the middle of the abdomen, to expose the peritoneum.Next, cut the upper small intestine from the stomach at the pyloric sphincter and the large intestine at the anal verge.Then use forceps to gently remove the mesentery and place the intestinal tract in prewarmed, oxyginated medium.Identify the area to be assessed for permeability, measuring the sections of the duodenum and jejunum relative to the stomach in the sections of the colon and ilium relative to the cecum to maintain consistency between the experimental animals.Note the presence of mucosa associated lymphoid tissues such as Peyer's patches, which can be identified as small nodules on the sarosal side of the lumen.Then, cut the selected section and use a 1 ml syringe to gently flush the lumenal contents of the segment into a petri dish containing 37
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol describes the use of excised intestinal tissue preparations or "intestinal sacs" as an ex vivo model of intestinal barrier function. This model may be used to assess integrity of both the epithelial barrier and the mucous gel layer at specific intestinal sites in animal models of digestive disease.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Digestive Health
Background
- Intestinal barrier function is crucial for maintaining gut health.
- Ex vivo models provide insights into intestinal physiology.
- Understanding barrier integrity can aid in digestive disease research.
- Intestinal sacs allow targeted studies of specific intestinal sites.
Purpose of Study
- To evaluate the integrity of the epithelial barrier.
- To assess the mucous gel layer's role in barrier function.
- To provide a reliable model for studying digestive diseases.
Methods Used
- Preparation of excised intestinal tissue.
- Creation of intestinal sacs for ex vivo analysis.
- Assessment of barrier integrity at various intestinal sites.
- Utilization of animal models to simulate digestive diseases.
Main Results
- Demonstrated the functionality of intestinal sacs in barrier studies.
- Identified variations in barrier integrity across intestinal sites.
- Showed the importance of the mucous gel layer in maintaining barrier function.
- Provided a framework for future digestive disease research.
Conclusions
- Intestinal sacs are effective for studying intestinal barrier function.
- Findings contribute to understanding digestive health.
- This model can facilitate research into various digestive diseases.
Frequently Asked Questions
Executive Industry Relevance
Assessing regional intestinal barrier integrity is critical for evaluating drug absorption and identifying site-specific epithelial dysfunction in gastrointestinal disease models. The ex vivo intestinal sac method provides a rapid, sensitive approach to measure apparent permeability (Papp) of molecules across defined intestinal segments, enabling mechanistic de-risking of oral drug candidates and supporting translational biomarker alignment in preclinical studies. This technique enhances predictive confidence by linking localized barrier changes to disease phenotypes, informing portfolio decisions on compound progression.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses regarding mucosal integrity loss in disease models.
- Operational Value: Supports functional target validation by quantifying uptake of specific molecules or bacteria during disease states.
- Predictive Value: Facilitates biological de-risking through site-specific permeability assessment across duodenum, jejunum, ileum, and colon.
Screening & Assay Development
- Assay Readiness: Prepares validated intestinal sacs for reproducible, quantitative permeability measurements.
- Standardization: Uses oxygenated medium and consistent segment identification to ensure assay reliability across experimental animals.
- Scalability: Enables rapid screening of compound transport or barrier integrity in defined gastrointestinal regions.
Translational & Preclinical Research
- Disease Relevance: Assesses regional epithelial barrier dysfunction in animal models of gastrointestinal disease, such as increased permeability in inflammatory bowel models.
- Translational Continuity: Connects discovery-stage barrier measurements to preclinical validation of drug absorption and mucous gel layer function.
- Risk-Adjusted Advancement: Informs go/no-go decisions by identifying barrier alterations that may affect drug exposure or toxicity.
Pipeline & Workflow Integration
The intestinal sac method fits within the discovery continuum from early barrier assessment to lead identification and preclinical evaluation, providing site-specific permeability data that supports compound screening and mechanistic de-risking.
- Discovery Biology: Supports hypothesis testing of barrier integrity loss and pathway clarification in gastrointestinal disease models.
- Screening: Delivers assay-ready tissue with quantitative Papp outputs for reliable compound evaluation across intestinal regions.
- Analytics: Generates apparent permeability measurements that enable comparison of transport rates under varying conditions.
- Translational Research: Links ex vivo barrier function to preclinical continuity by modeling human-relevant intestinal sites.
- Enterprise Reuse: Establishes a reusable platform for assessing drug absorption and barrier integrity across multiple disease models and compound series.
Operational & Enterprise Impact
- Scientific Value: Provides predictive confidence in target validation by reducing mechanistic ambiguity in barrier function.
- Operational Value: Ensures standardization, reproducibility, and scalability of permeability assessments across intestinal sites.
- Strategic Value: Improves go/no-go decisions, capital efficiency, and reduces late-stage biological risk from poor absorption predictions.
- Portfolio Impact: Enables risk-adjusted prioritization based on region-specific barrier integrity and drug transport profiles.
Implementation Considerations
- Requires expertise in intestinal dissection, segment identification, and mucosal handling.
- Depends on oxygenated medium perfusion and temperature-controlled incubation for tissue viability.
- Necessitates standardized protocols for sac preparation and luminal flushing to ensure consistency.
- Involves adaptation considerations for different model systems and intestinal regions.
- Limited by ex vivo tissue viability duration, requiring timely permeability measurements post-dissection.
